key: cord-0893379-awwqa1bt
authors: Bianconi, Vanessa; Mannarino, Massimo R.; Figorilli, Filippo; Cosentini, Elena; Batori, Giuseppe; Marini, Ettore; Lombardini, Rita; Gargaro, Marco; Fallarino, Francesca; Scarponi, Anna Maria; Sahebkar, Amirhossein; Pirro, Matteo
title: Prevalence of vitamin D deficiency and its prognostic impact in hospitalized patients with COVID-19
date: 2021-07-01
journal: Nutrition
DOI: 10.1016/j.nut.2021.111408
sha: 2c1bfbe11169f2d8d385715bcf00e79d3945d61d
doc_id: 893379
cord_uid: awwqa1bt

OBJECTIVE: . Despite hypovitaminosis D appears to be highly prevalent in patients with coronavirus disease 2019 (COVID-19), its impact on their prognosis remains unclear. RESEARCH METHODS & PROCEDURES: . In this study serum 25-hydroxyvitamin D (Vit-D) level was measured in 200 hospitalized patients with COVID-19. The association between Vit-D and the composite endpoint of intensive care unit (ICU) admission/in-hospital death was explored using univariable and multivariable analyses. Also, serum Vit-D level in COVID-19 patients was compared with that in age- and sex-balanced COVID-19 negative controls (i.e. 50 inpatients with sepsis). RESULTS: . Serum Vit-D level was comparable between COVID-19 patients and COVID-19 negative inpatients with sepsis (p = 0.397). No significant differences were found in serum Vit-D level according to COVID-19 severity at hospital admission (p = 0.299). Incidence rates of the composite endpoint of ICU admission/in-hospital death did not differ significantly between patients with either Vit-D deficiency (i.e. Vit-D <20 ng/mL) or severe Vit-D deficiency (i.e. Vit-D <12 ng/mL) and those without (31% versus 35% with p = 0.649 and 34% versus 30% with p = 0.593, respectively). Vit-D level and status (i.e. Vit-D deficiency and severe Vit-D deficiency) were not prospectively associated with the risk of the composite endpoint of ICU admission/in-hospital death (p > 0.05 for all Cox regression models). CONCLUSIONS: . Irrespective of the potential usefulness of Vit-D measurement for guiding appropriate supplementation, Vit-D does not appear to provide helpful information for the stratification of in-hospital prognosis in patients with COVID-19.

BUN, blood urea nitrogen; CCI, Charlson Comorbidity Index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; COVID-19, Coronavirus disease 2019; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; FiO2, fraction of inspiration oxygen; ICU, intensive care unit; NIV, non-invasive ventilation; PaO2, partial pressure of oxygen; RT-PCR, real-time reversetranscriptase-PCR; LDH, lactate dehydrogenase; SpO2, peripheral oxygen saturation; Vit-D, 25hydroxyvitamin D.

Coronavirus disease 2019 continues to be a terrifying challenge for the health systems worldwide, as daily reported by the World Health Organization Official Updates [1] . In the hospital setting, therapeutic efforts to manage patients with the most common complications of this disease are not always effective [2] . Thus, about 20% of patients hospitalized with COVID-19 are transferred to intensive care units (ICUs) and 20% die from pulmonary and extra-pulmonary complications of the disease [3] . The most unfavorable prognosis, often dictated by the lack of effective specific therapies, is recorded in older patients with a greater frailty [4, 5] . However, identifying circulating biomarkers possibly suggesting pathophysiological mechanisms and clinical evolution of the disease irrespective of age and comorbidities as well as orienting the diagnostic and therapeutic choices, could be very helpful.

The major circulating form of vitamin D, that is 25-hydroxyvitamin D (Vit-D) , is produced by the hepatic hydroxylation of previtamin D, which in turn is obtained in the skin from 7dehydrocholesterol by the action of UVB rays. Subsequently, Vit-D is converted into 1,25dihydroxyvitamin D (calcitriol), that is the biologically active form of vitamin D, through another hydroxylation reaction taking place in the kidney and other tissues/cells (e.g. immune cells) [6, 7] .

Beyond having a key role in calcium homeostasis [8] , Vit-D can exert direct antiviral effects and can cooperate with type I interferon to enhance antiviral responses [9, 10] . In addition, it can exert an immune-modulating action by regulating the production of inflammatory cytokines and inhibiting the proliferation of inflammatory cells [10] .

By virtue of its antiviral and immuno-modulating action, Vit-D could play a favorable role in the natural history of COVID-19 [11] . On the contrary, Vit-D deficiency status could be a prognostically unfavorable element in this infectious disease [11] . To date, various observational studies having assessed Vit-D level in patients with COVID-19 have shown a unique result, namely the high prevalence of Vit-D deficiency [12, 13] . Also, a recent meta-analysis of observational studies has shown that patients with Vit-D deficiency are more likely to get SARS-CoV-2 infection [14] . However, a similar concordance of results was not observed with respect to the association between Vit-D and COVID-19-related outcomes. In fact, the inverse associations between Vit-D level and both COVID-19 severity and prognosis that emerged in some studies [15] [16] [17] were not always confirmed in others [18] [19] [20] [21] [22] .

To make the link between serum Vit-D level and prognosis even more intricate, some intervention studies have found that Vit-D supplementation could reduce the transfer of COVID-19 patients to ICU or their risk of death [23] . However, in other studies, Vit-D supplementation had no favorable effects on the clinical course of COVID-19 [24, 25] .

In this study we investigated the prevalence of Vit-D deficiency and severe Vit-D deficiency in COVID-19 patients hospitalized in an internal medicine ward as compared to that in COVID-19 negative patients admitted with sepsis. In addition, considering the diverging literature results, we explored the prospective association between Vit-D and risk of ICU admission/in-hospital death, as a composite endpoint, in hospitalized patients with COVID-19.

Hospitalized COVID-19 patients admitted to the Unit of Internal Medicine of the "Santa Maria della Misericordia" Hospital of Perugia (Italy) from December 2020 to March 2021 were consecutively enrolled. The study protocol was developed in accordance with the principles of the Helsinki Declaration and was approved by the local ethics committee. Inclusion criteria were the following ones: 1) age ≥18 years; 2) a positive result on real-time reverse-transcriptase-PCR (RT-PCR) assays testing for SARS-CoV-2 on nasal or pharyngeal swab specimens at hospital admission; 3) informed written consent. Ongoing or previous (within the last six months) Vit-D supplementation was an exclusion criterion.

A control group was enrolled including 50 age-and sex-balanced COVID-19 negative patients who were admitted with sepsis to the Unit of Internal Medicine of the "Santa Maria della Misericordia" Hospital of Perugia (Italy) from December 2020 to March 2021. Inclusion criteria were the following ones: 1) age ≥18 years; 2) a negative result on RT-PCR assays testing for SARS-CoV-2 on nasal or pharyngeal swab specimens at hospital admission; 3) informed written consent; 4) diagnosis of sepsis according to the Sepsis-3 criteria [26] at hospital admission. Ongoing or previous (within the last six months) Vit-D supplementation was an exclusion criterion. ng/mL [27] . Radiological diagnosis of pneumonia was based on the presence of at least one of the following radio-graphic signs in either chest X-ray or high-resolution computed tomography: mono or bilateral consolidations, ground glass opacities, and crazy paving pattern. Respiratory insufficiency was defined as the presence of peripheral oxygen saturation (SpO2) ≤90% and/or arterial partial pressure of oxygen (PaO2) ≤60 mmHg and/or need of oxygen support at admission. Calculated PaO2/fraction of inspiration oxygen ratio (PaO2/FiO2) <300 was used to define the presence of respiratory distress. The CURB-65 score was estimated for each patient by integrating five clinical/laboratory data at admission [i.e. 1-confusion (1 point); 2 -BUN >19 mg/dL (1 point);

3 -respiratory rate ≥30/minute (1 point); 4 -systolic blood pressure <90 mmHg or diastolic blood pressure ≤60 mmHg, as assessed through sphygmomanometer (1 point); 5 -age ≥65 years (1 point)] [28, 29] . The Charlson Comorbidity Index (CCI) was calculated for each patient by integrating information on coexisting medical conditions [30] . Data on clinical course [i.e. in-hospital medical treatments and need of non-invasive ventilation (NIV)] and in-hospital outcomes (i.e. the composite endpoint of ICU admission/in-hospital death or hospital discharge) were collected and registered in medical records.

The study sample size was calculated based on the results of a previous study [31] , by assuming a type I error =0.05, a type II error =0.2, a ratio of the unexposed group (Vit-D 20 ng/mL) to exposed group (Vit-D <20 ng/mL) =0.56, a probability of event (i.e. ICU admission/in-hospital death) in the unexposed group =0.02, and a probability of event in the exposed group =0.13. While the estimated sample size was of 206 patients, we performed our analysis in 200 patients, as an interim analysis. The SPSS statistical package, release 24.0 (SPSS Inc, Chicago, Ill), was used for all statistical analyses. The Shapiro test was used to verify the normality of the study variables.

Categorical variables were expressed as percentages, while continuous variables were expressed as mean ± standard deviation or median and interquartile ranges. The independent samples t-test, the Mann-Whitney U-test, and the chi-squared test were used for two-group comparisons. The Kruskal-Wallis test was used for multiple-group comparisons of non-parametric variables. The chi-squared test was used to compare multiple independent categorical variables. Correlation analyses between the study variables were performed using the Pearson's and Spearman's coefficients of correlation.

Time-to-event analyses were performed to assess the association between Vit-D and the composite endpoint of ICU admission/in-hospital death (primary endpoint) as well as the association between Vit-D and in-hospital death as single endpoint (secondary endpoint).

For five patients, who did not meet the aforementioned endpoints and were still hospitalized at the time of analysis, the event date was censored on April 3, 2021. The association between Vit-D, either as continuous or categorical variable (i.e. serum Vit-D level, Vit-D deficiency, and severe Vit-D deficiency) and either the composite endpoint of ICU admission/in-hospital death or inhospital death as single endpoint was evaluated through Cox proportional hazard models by adjusting for potential confounders. Statistical significance was assumed if a null hypothesis could be rejected at p <0.05.

The main characteristics of 200 COVID-19 patients categorized according to the presence or absence of Vit-D deficiency (i.e. Vit-D <20 ng/mL versus Vit-D 20 ng/mL) are shown in Table 1 .

The prevalent symptoms reported at hospital admission were fever, dyspnea, and cough (65%, 64% and 41% of patients, respectively). According to the National Institutes of Health classification of Covariates of Vit-D Age was significantly lower in patients with Vit-D deficiency as compared to those without (Table   1) . A significant crude correlation was found between Vit-D and albumin (rho=0.149, p=0.037). No significant difference was found in serum Vit-D level between patients who were admitted to ICU or died as compared to those who were not admitted to ICU/were discharged alive (Table 2) , nor between patients who died and those who did not (Supplementary Table 1 ). No significant differences were found in the prevalence of Vit-D deficiency or severe Vit-D deficiency between patients who met the composite outcome of ICU admission/in-hospital death and those who did not (p=0.649 and p=0.593, respectively), nor between survivors and non-survivors (p=1.000 and p=0.357 respectively). Incidence rates of the composite endpoint of ICU admission/in-hospital death did not differ significantly between patients with either Vit-D deficiency (i.e. Vit-D <20 ng/mL) or severe Vit-D deficiency (i.e. Vit-D <12 ng/mL) and those without (31% versus 35% and p=0.649 for Vit-D deficiency, 34% versus 30% and p=0.593 for severe Vit-D deficiency, respectively). Rates of in-hospital death did not differ significantly across serum Vit-D quintiles (Vit-D <6,1 ng/mL in 1 st quintile, 6.1 ng/mL Vit-D <9.7 ng/mL in 2 nd quintile, 9,7 ng/mL Vit-D <13.9 ng/mL in 3 rd quintile, 13.9 ng/mLVit-D <20 ng/mL in 4 th quintile, Vit-D 20 ng/mL in 5 th Table 2 ).

The main characteristics of age-and sex-balanced COVID-19 negative controls are reported in Supplementary Table 3. Serum Vit-D level was comparable between COVID-19 patients and COVID-19 negative inpatients with sepsis (p=0.397). Prevalence of Vit-D deficiency was 80% and 78% in COVID-19 patients and COVID-19 negative inpatients with sepsis, respectively (p>0.05 for the comparison between the two groups). Prevalence of severe Vit-D deficiency was 53% and 50% in COVID-19 patients and COVID-19 negative inpatients with sepsis, respectively (p>0.05 for the comparison between the two groups).

In this prospective study enrolling patients hospitalized for COVID-19 two main results emerged.

First, patients with COVID-19 had comparable Vit-D level to that of age-and sex-balanced COVID-19 negative inpatients with sepsis. Second, serum Vit-D level was not cross-sectionally associated with any of the clinical parameters of COVID-19 severity nor it was prospectively associated with in-hospital prognosis of COVID-19 patients.

In line with literature data [33, 34] , a high prevalence of Vit-D deficiency and severe Vit-D deficiency emerged in this cohort of hospitalized patients with COVID-19, with 80% and 53% of enrolled patients having shown these two conditions, respectively. However, it is intriguing to note that the prevalence of Vit-D deficiency and severe Vit-D deficiency was not dissimilar to that observed in COVID-19 negative inpatients with sepsis. This finding suggests a possible pathophysiological link between Vit-D and infections. In this regard, two different albeit nonmutually exclusive speculations are plausible, the first relating to a possible direct causality and the second to a possible reverse causation between Vit-D and infections. With regard to the first hypothesis (i.e. direct causality), the state of Vit-D deficiency, possibly pre-existing to the contact with pathogens, could affect an increased probability of getting both viral and bacterial infections.

Indeed, there is evidence showing that Vit-D deficiency can promote different viral infections [35] , including COVID-19 [12] . In addition, a significant association between hypovitaminosis D and increased susceptibility to sepsis has been reported [36] . However, although Vit-D plays an undoubted role in modulating the immune response to infections [10] , it should be emphasized that the literature on this topic currently remains very controversial [37] . On the other hand, also reverse causation could explain the association between low serum Vit-D level and COVID-19. In this regard, a combination of factors characterizing the population affected by COVID-19 (e.g. the preferential involvement of the older age groups, the state of profound debilitation and malnutrition related to the course of the disease, the reduced sun exposure due to the default isolation preceding and following hospitalization) [4, 5, 38, 39] , may contribute to reduce serum level of Vit-D. Partly supporting this interpretation, a non-specific marker of nutritional status as reduced albumin, which is particularly prevalent among COVID-19 patients [40] , was directly correlated with Vit-D level in this study.

Nonetheless, regardless of the direction of the association between COVID-19 and hypovitaminosis D, it should be emphasized that this latter condition has been proposed to alter the homeostasis of numerous biological processes, thereby possibly promoting the progression of the disease independently from its influence on immune response.

In this study we did not find any association between Vit-D and any clinical parameter of COVID-19 severity at hospital admission or during hospitalization, including the presence of radiologic signs of pneumonia, respiratory insufficiency, respiratory distress, and the need of NIV. Also, serum Vit-D level, Vit-D deficiency, and severe Vit-D deficiency were not prospectively associated with the composite outcome of ICU admission/in-hospital death nor with in-hospital death as single endpoint (Table 3 and Supplementary Table 2 ). Conversely, as already reported in previous studies [41, 42] , PaO2/FiO2 and type 2 diabetes were significant and independent predictors of poor prognosis also in this cohort of hospitalized patients with COVID-19. Our finding of the lack of an association between serum Vit-D level and severity of COVID-19 fits into the context of a series of conflicting observational studies with either a retrospective or prospective design exploring the association between Vit-D and COVID-19 severity/outcomes. Indeed, some retrospective studies in patients hospitalized for COVID-19 have found a significant association between low Vit-D level and either disease severity or in-hospital outcomes [43] [44] [45] , while others have not confirmed this relationship [46, 47] . Similarly, discrepant results have been highlighted in some prospective studies examining the association between low Vit-D level and either COVID-19 severity or prognosis [18, 19, 31, 48, 49] . Also, further fueling inconsistency of literature on Vit-D, in contrast with previous studies suggesting a possible J-shaped relationship between serum Vit-D and either cardiovascular mortality or all-cause mortality [50, 51] , we did not find any significant difference in rates of in-hospital death across Vit-D quintiles (Supplementary Figure 2) .

The reasons why the results of this study may diverge or agree with those from other studies may be the most varied. First of all, the prospective analysis of the association between Vit-D and COVID-19 prognosis which was performed in this study provides more reliable results than those derived from retrospective studies, due to the intrinsic limitations of the latter ones (e.g. impossibility of assessing the temporal relationship between the study variables, and potential confounding effect due to unmeasured variables). In addition, it should be noted that, as compared to other prospective studies that have documented a negative impact of Vit-D deficiency on the prognosis of patients with COVID-19, the population of this study was older [18, 19, [47] [48] [49] ; this might have masked a possible weak association between low Vit-D level and in-hospital prognosis. Furthermore, in this study the period of observation lasted until the occurrence of ICU admission/in-hospital death or until the conclusion of hospitalization (i.e. on average 13 days for patients who were discharged alive); therefore, a relatively short-term follow-up might have compromised the possibility of detecting a long-term impact of Vit-D deficiency on COVID-19 prognosis. Based on these observations, our findings cannot be generalized to younger populations of COVID-19 patients, nor they can be extended to the relationship between Vit-D and long-term prognosis of COVID-19 patients.

However, it cannot be excluded that discrepancies between previous studies and our study may be at least in part attributed to different methods of measuring circulating levels of Vit-D. To this regard, it should be considered that measurement of total serum Vit-D may have the limitation of underestimating possible interindividual differences in the proportion of free Vit-D, that is the bioactive form, and Vit-D bound to Vit-D binding protein (DBP). Indeed, there is a well-known high variability in DBP affinity for Vit-D, which can be affected by several DBP genetic variants and pathophysiological conditions [52] . In addition, DBP circulating levels can be significantly influenced by the activation of systemic inflammation [52] .

Overall, the disagreement of results from observational studies relating to the relationship between Vit-D level and COVID-19 prognosis mirrors discrepancies which emerged in the few intervention studies exploring the effects of Vit-D supplementation in patients with COVID-19 [23] [24] [25] .

Limitations Some limitations of this study deserve attention. First, the population examined in this study was numerically limited, confined to a relatively advanced age group and followed-up for the relatively short period of hospitalization. Therefore, generalizability of the observed results to other clinical settings must be considered with extreme caution. Second, the relatively small sample size which was included in the interim analysis, may undermine the reliability of the observed results. Third, the assay we used to measure serum Vit-D has the intrinsic limitation of accounting only for total Vit-D, which is mostly bound to DBP; accordingly, it cannot be excluded that some factors influencing circulating DBP levels, including systemic inflammation [52] , may have confounded Vit-D measurements. Such a limitation might be overcome by demonstrating the replicability of the study results when incorporating also free Vit-D measures or, alternatively, pre-COVID- 19 Vit-D measures from the same population. However, in the setting of our study, neither the option of measuring free Vit-D nor that of recording pre-COVID- 19 Vit-D measures from the same population was available. Finally, the control population (i.e. COVID-19 negative inpatients with sepsis), albeit being balanced in terms of age and sex with that of COVID-19 patients, was numerically too small to allow an adequate adjustment of the between-group differences in Vit-D for a consistent number of confounding factors. However, it must be underlined that comparable results have been previously reported for the prevalence of hypovitaminosis D in populations similar to our control group [53] [54] .

In patients with COVID-19 hospitalized in an internal medicine ward, the prevalence of Vit-D deficiency is extremely high but not dissimilar to that seen in non-COVID-19 patients hospitalized 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. 

WHO Official Updates -Coronavirus Disease 2020

Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ? Drugs

Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19

Outcomes and Mortality Among Adults Hospitalized With COVID-19 at US Medical Centers

Age, Frailty, and Comorbidity as Prognostic Factors for Short-Term Outcomes in Patients With Coronavirus Disease 2019 in Geriatric Care

Clinical practice. Vitamin D insufficiency

Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase

Vitamin D Activity and Metabolism in Bone

Insights in Immuno-Nutrition: Vitamin D as a Potent Immunomodulator

Vitamin D and immune regulation: antibacterial, antiviral, anti-inflammatory

Increased risk for COVID-19 in patients with vitamin D deficiency

Low vitamin D status is associated with coronavirus disease 2019 out-comes: a systematic review and meta-analysis

Association of Vitamin D Status with SARS-CoV-2 Infection or COVID-19 Severity: A Systematic Review and Meta-analysis

The Impact of Vitamin D Level on COVID-19 Infection: Systematic Re-view and Meta-Analysis. Front Public Health

Vitamin D Status Is Associated With In-Hospital Mortality and Mechanical Ventilation: A Cohort of COVID-19 Hospitalized Patients

Vitamin D Deficiency and Low Serum Calcium as Predictors of Poor Prognosis in Patients with Severe COVID-19

Evaluation of vitamin D levels in COVID-19 patients re-ferred to Labafinejad hospital in Tehran and its relationship with disease severity and mortality

Impact of Vitamin D Deficiency on COVID-19-A Prospective Analysis from the CovILD Registry

Vitamin D status and outcomes for hospitalised older patients with COVID

Vitamin D and COVID-19 infection and mortality in UK Biobank

Factors Associated with Hospitalization and Disease Severity in a Ra-cially and Ethnically Diverse Population of COVID-19 Patients. medRxiv 2020.06.25

Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19

Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothe-sis-Generating Study

Vitamin D supplementation, COVID-19 & Disease Severity: A meta-analysis

Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Vitamin D deficiency 2.0: an update on the current status worldwide

NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial

Age-specific relationship of aortic pulse wave velocity with left ventricular geometry and function in hypertension

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Vitamin D Deficiency and Outcome of COVID-19 Patients

COVID-19 treatment guidelins

Vitamin D Status in Hospitalized Patients with SARS-CoV-2 Infection

Vitamin D deficiency among patients with COVID-19: case series and recent literature review

Striker, R. Vitamin D and the anti-viral state

Significant association between vitamin D deficiency and sepsis: a systematic re-view and meta-analysis

Sorting Out Whether Vitamin D Deficiency Raises COVID-19 Risk

Weight loss, malnutrition, and cachexia in COVID-19: facts and numbers

Does solar ultraviolet radiation play a role in COVID-19 infection and deaths? An environmental ecological study in Italy

Is Albumin Predictor of Mortality in COVID-19?

Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Preexisting Type 2 Diabetes

Vitamin D Deficiency Is Associated with COVID-19 Incidence and Disease Sever-ity in Chinese People

The association between vita-min D levels and the clinical severity and inflammation markers in pediatric COVID-19 patients: single-center experience from a pandemic hospital

Association of Vitamin D Status With Hospital Morbidity and Mortality in Adult Hospitalized Patients With COVID-19

Vitamin D -contrary to vitamin K -does not associate with clinical outcome in hospitalized COVID-19 patients

Vitamin D Status in Hospitalized Patients with SARS-CoV-2 Infection

Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19

Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers

A Reverse J-Shaped Association Between Serum 25-Hydroxyvitamin D and Cardiovascular Disease Mortality: The CopD Study

Is there a reverse J-shaped association between 25-hydroxyvitamin D and all-cause mortality? Results from the U.S. nationally representative NHANES

Vitamin D Binding Protein, Total and Free Vitamin D Levels in Different Physiological and Pathophysiological Conditions. Front Endocrinol (Lausanne)

Serum 1,25-dihydroxyvitamin D: an outcome prognos-ticator in human sepsis

25(OH)D and 1,25(OH)D vitamin D fails to predict sepsis and mortality in a prospective cohort study

Comorbidity Index; COPD, chronic obstructive pulmonary disease; COVID-19

direct oral anticoagulants; eGFR, estimated glomerular filtration rate; FiO2, fraction of inspiration oxygen; LDH lactate dehydrogenase; LMWH, low molecular weight heparin; OHA, oral Hypoglycemic agents

25-hydroxyvitamin D; VKAs, vitamin-K antagonists

* p for the comparison between COVID-19 patients with and without Vit-D deficiency

BMI, body mass index

calcium channel blockers; CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; COVID-19

CV, cardiovascular; DBP, diastolic blood pressure; DOACs, direct oral anticoagulants; eGFR, estimated glomerular filtration rate

FiO2, fraction of inspiration oxygen

intensive care unit; LDH lactate dehydrogenase; LMWH, low molecular weight heparin

OHA, oral hypoglycemic agents

systolic blood pressure

Acknowledgments: None to declare.

The authors declare no conflict of interest.